Back to search results

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Conditions

Clonal Cytopenia of Undetermined Significance · High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Hodgkin Lymphoma · Recurrent Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Lymphoma · Chronic Myelomonocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States

    Contact: Study coordinator (Danielle Mutschler) · Mutschler.Danielle@mayo.edu · 507-377-4817
    Contact: Principal Investigator (Stephan D. Thome, M.D.)

  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Thomas E. Witzig, M.D.)

  • Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Eyad S. Al-Hattab, M.D.)

  • Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States

Study leads

  • Thomas E Witzig, M.D.

    Principal Investigator

    Mayo Clinic

View source on ClinicalTrials.gov(opens in a new tab)